Scientific Sessions

Program​

​

“High yield content, with each talk short and focused” – event participant, 2025

​​

Come prepared for a full, intense day of learning!

​

The program features two keynote presentations:

• The role of inflammation in pulmonary arterial hypertension
  Dr. Stephen Archer & Dr. Patricia Lima, Queen’s University

• Disentangling the central, peripheral and hematological mechanisms of benefit from sotatercept
  Dr. Yogesh Reddy, MBBS, MSc, Mayo Clinic

 

Other topics in this year’s program (subject to change):

• Exploring integrin a5B1 as a Potential Therapeutic Target for PAH

• Endothelial Senescence as a Therapeutic Target in PAH

• Spotting CTEPH

• The Hemodynamics and Pulmonary Vascular Physiology of Group 4 PH

• Pulmonary Vascular Recruitment During Exercise

• Imaging the Pulmonary Vascular Bed

• Seeing the Right Heart: AI-Derived RV Function and PH Screening from Standard Echocardiography

• Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in PAH

• Targeting Cancer-Like Endothelial Cell Growth in PAH Using CAR-NK Cell Immunotherapy

• The Perils of Group III PH

• Porto-pulmonary hypertension

​

The program is co-developed by the Pulmonary Hypertension Association of Canada and the Canadian Thoracic Society and is planned to achieve scientific integrity, objectivity, and balance.

​

In conjunction with PHA Canada’s 2026 Pulmonary Hypertension Community Conference.​